MSF sent another open letter urging AbbVie to make glecaprevir/pibrentasvir (G/P) accessible for people with hepatitis C in LMICs

Médecins Sans Frontières (MSF) Access Campaign wrote an open letter to pharmaceutical corporation AbbVie to express our urgent need for glecaprevir/pibrentasvir (G/P) combination to treat people with hepatitis C.

Médecins Sans Frontières (MSF) Access Campaign wrote a letter of support to the Malaysian government commending the issuance of a government use licence to enable access to an affordable version of the hepatitis C drug sofosbuvir. The ...

The grounds for opposing patent applications for velpatasvir

This issue brief provides information on currently available hepatitis C diagnostics and treatments, including pricing and registration information from manufacturers of direct-acting antivirals (DAAs). Reasons underlying the continued ...

Médecins Sans Frontières/Doctors Without Borders (MSF) plans to start treating people infected with hepatitis C virus in nine countries.